Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S156-9. Epub 2010 Oct 28.

Use of methotrexate in patients with systemic lupus erythematosus and primary Sjögren's syndrome.

Author information

  • 1Division of Rheumatology, Department of Medicine III, University Center Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.

Abstract

While there is still no convincing evidence that methotrexate is of benefit in primary Sjögren's syndrome, the SLE evidence on this rheumatology anchor drug is substantial. In fact, there are randomised controlled trials showing the benefit for methotrexate on overall SLE activity, reduction in glucocorticoid doses, and effects on lupus arthritis and lupus skin manifestations. In addition, methotrexate may be helpful in vasculitis, haematological manifestations, and perhaps kidney disease. Intrathecal methotrexate was successfully used in neuropsychiatric SLE. Taken together, using methotrexate in SLE is not only a common approach, but, at least in part, supported by evidence from clinical trials.

PMID:
21044451
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Clinical and Experimental Rheumatology
    Loading ...
    Write to the Help Desk